From stability to dynamics: understanding molecular mechanisms of regulatory T cells through Foxp3 transcriptional dynamics

D. Bending,† and M. Ono†
† Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, UK, and † Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London, UK

Summary

Studies on regulatory T cells (T_{reg}) have focused on thymic T_{reg} as a stable lineage of immunosuppressive T cells, the differentiation of which is controlled by the transcription factor forkhead box protein 3 (Foxp3). This lineage perspective, however, may constrain hypotheses regarding the role of Foxp3 and T_{reg} in vivo, particularly in clinical settings and immunotherapy development. In this review, we synthesize a new perspective on the role of Foxp3 as a dynamically expressed gene, and thereby revisit the molecular mechanisms for the transcriptional regulation of Foxp3. In particular, we introduce a recent advancement in the study of Foxp3-mediated T cell regulation through the development of the Timer of cell kinetics and activity (Tocky) system, and show that the investigation of Foxp3 transcriptional dynamics can reveal temporal changes in the differentiation and function of T_{reg} in vivo. We highlight the role of Foxp3 as a gene downstream of T cell receptor (TCR) signalling and show that temporally persistent TCR signals initiate Foxp3 transcription in self-reactive thymocytes. In addition, we feature the autoregulatory transcriptional circuit for the Foxp3 gene as a mechanism for consolidating T_{reg} differentiation and activating their suppressive functions. Furthermore, we explore the potential mechanisms behind the dynamic regulation of epigenetic modifications and chromatin architecture for Foxp3 transcription. Lastly, we discuss the clinical relevance of temporal changes in the differentiation and activation of T_{reg}.

Keywords: Foxp3, Nr4a3, regulatory T cells (T_{reg}), Time of cell kinetics and activity (Tocky), transcriptional autoregulatory circuit

Introduction

Dynamics of Foxp3 transcription as a key to understanding regulatory T cell-mediated immune regulation

It is widely considered that regulatory T cells (T_{reg}) constitute a distinct lineage of CD4+ T cells dedicated for immunosuppression [1]. Key evidence for the distinct lineage include: (i) T_{reg} development is controlled by the transcription factor Foxp3 [2]; and (ii) the development of T_{reg} in the thymus is delayed to after that of other T cells under physiological conditions [3]. However, accumulating evidence shows the simultaneous development of T_{reg} and other T cells [4,5] and T_{reg} plasticity is now widely recognized, as T_{reg} can lose forkhead box protein 3 (Foxp3) expression and become effector T cells (ex-T_{reg}) during inflammation [6,7]. Thus, studies on dynamic changes in the differentiation and activation status of T_{reg} – and other T cells – in vivo is essential for understanding Foxp3-mediated T cell regulation. This dynamic perspective is important not only for basic research but also clinical research and immunotherapy development, which is illustrated by the catastrophic clinical trial of the superagonistic anti-CD28 antibody TGN1412 in 2006. TGN1412 was developed as an immunosuppressive treatment after an anti-CD28 antibody was found to suppress autoimmune reactions in rodent models [8]. TGN1412 was thus designed to bind to the CD28...
molecule on the surface of T\textsubscript{reg}, which would, in turn, theoretically suppress non-T\textsubscript{reg} [9]. This trial, however, resulted in catastrophe, where all six volunteers given TGN1412 developed a ‘cytokine storm’ due to stimulation of a significant proportion of T cells [10]. Later, it was found that CD28 molecules in memory-phenotype T cells are down-regulated in primates – which does not occur in humans – and this species difference was deemed to be the major cause of the incident [11]. Meanwhile, Vitetta and Ghetie pointed out that T\textsubscript{reg} and non-T\textsubscript{reg} may not represent strictly separate lineages, and therefore the assumption of specific activation of T\textsubscript{reg} may have been inappropriate [12]. In fact, basic studies later showed the plasticity of T\textsubscript{reg}: T\textsubscript{reg} may lose Foxp3 expression during inflammation and non-T\textsubscript{reg} may acquire Foxp3 expression [13]. Summarizing, the case provides two important lessons: first, the concepts of lineage stability may constrain hypotheses, which can be detrimental in clinical settings; and secondly, it is fundamental to investigate the dynamic changes in the differentiation and activation statuses of T\textsubscript{reg} and other T cells \textit{in vivo}, which are still poorly understood.

The key evidence of Foxp3 as the lineage-specification transcription factor is that mutations in the Foxp3/FOX3 gene can lead to autoimmune disease in both mice [14] and humans [15]. However, this does not preclude the dynamic induction of Foxp3 as a negative regulator in response to T cell activation. In fact, Foxp3 expression can be induced solely by T cell receptor (TCR) signals in human T cells [16] and, although less efficiently, also in mice [17], and the induction is enhanced by transforming growth factor (TGF)-\(\beta\) and interleukin (IL)-2 [18]. TGF-\(\beta\) is produced by activated antigen-presenting cells such as dendritic cells [19] and macrophages [20], while IL-2 is produced mainly by activated T cells [10]. Later, it was found that CD28 molecules in memory-phenotype T cells are down-regulated in primates – which does not occur in humans – and this species difference was deemed to be the major cause of the incident [11]. Meanwhile, Vitetta and Ghetie pointed out that T\textsubscript{reg} and non-T\textsubscript{reg} may not represent strictly separate lineages, and therefore the assumption of specific activation of T\textsubscript{reg} may have been inappropriate [12]. In fact, basic studies later showed the plasticity of T\textsubscript{reg}: T\textsubscript{reg} may lose Foxp3 expression during inflammation and non-T\textsubscript{reg} may acquire Foxp3 expression [13]. Summarizing, the case provides two important lessons: first, the concepts of lineage stability may constrain hypotheses, which can be detrimental in clinical settings; and secondly, it is fundamental to investigate the dynamic changes in the differentiation and activation statuses of T\textsubscript{reg} and other T cells \textit{in vivo}, which are still poorly understood.

The current understanding of T\textsubscript{reg} differentiation and function is based significantly on evidence obtained by Foxp3 fluorescent protein (FP) reporters such as enhanced green fluorescent protein (EGFP) [28,29] and fate mapping systems for the Foxp3 gene (e.g. Foxp3\textsuperscript{ERT2CreGFP}:Rosa26\textsuperscript{RFP} [17] and Foxp3\textsuperscript{ERT2CreGFP}:Rosa26\textsuperscript{FFP} [30]). Notably, all these systems rely upon stable FPs such as GFP, the half-life of which is longer than 56 h. Therefore, temporal changes in Foxp3 transcription shorter than 2–3 days cannot be investigated by these reporter systems.

In order to understand the \textit{in-vivo} dynamics of those molecular mechanisms underlying the differentiation and function of T\textsubscript{reg}, we have recently developed the Tocky system using Fluorescent Timer protein (Timer). Timer proteins exhibit a short-lived blue fluorescent form, before maturation to the stable red state [27,31]. The half-life of blue fluorescence is \(\sim 4\) h [26,27] and that of the mature red fluorescence is \(\sim 5\) days [26]. Thus, blue and red fluorescence (blue and red) provide a measurement of both the ‘real-time’ activity and the history of gene transcription [26]. Tocky uses this information to analyse dynamic changes quantitatively in transcriptional activities during cellular activation and differentiation [27]. Importantly, we have identified three characteristic dynamics of transcription in the Tocky system: blue\textsuperscript{+}red\textsuperscript{−} cells are those that have just initiated transcription (new); blue\textsuperscript{+}red\textsuperscript{+} cells along the diagonal line between blue and red axes are those with sustained transcription, accumulating both blue and red form proteins (persistent); and blue\textsuperscript{−}red\textsuperscript{+} cells are those that have recently down-regulated gene expression under the detection threshold of flow cytometry and are inactive in transcription of the gene (arrested or inactive) [27] (Fig. 1).

\textbf{Foxp3 transcription is controlled mainly by 5’ upstream sequences and conserved non-coding sequences (CNS) 1–3 in intronic regions 7,32–34. Importantly, while TCR signals (together with TGF-\(\beta\) and IL-2 signals) induce Foxp3 expression in any T cells \textit{in vitro} [18], naturally arising Foxp3 expression is found mainly in self-reactive T cells in non-inflammatory conditions [1]. Thus, we will classify the mechanisms for Foxp3 transcription into two groups, as follows:}

1. \textbf{Mechanisms for the activation of Foxp3 transcription: these are used during thymic T\textsubscript{reg} selection and peripheral T\textsubscript{reg} differentiation and are potentially involved in the mechanism for tonic TCR signal-mediated activation of Foxp3 transcription.}

2. \textbf{Mechanisms for the consolidation and tuning of Foxp3 transcription: these are used for sustaining Foxp3 transcription over time, which induces effector T\textsubscript{reg}}
differentiation and the dynamic regulation of epigenetic modifications, such as demethylation of CpG islands in enhancer regions (Fig. 2).

Mechanisms for the activation of Foxp3 transcription

**Foxp3 as a TCR signal downstream gene.** The differentiation and function of T<sub>reg</sub> is under the control of TCR signals [35-38]. In the thymus, the recognition of cognate antigen induces not only negative selection but also the differentiation of CD25<sup>+</sup>Foxp3<sup>+</sup> T<sub>reg</sub> from CD4-SP cells using transgenic TCR systems [39-41]. Conversely, TCR transgenic mice recombine activating gene (Rag)-deficient backgrounds lack Foxp3<sup>+</sup> T cells due to the absence of self-antigen recognition [42,43]. The analysis of TCR signals using reporter mice have provided insights into the mechanism for TCR-mediated T<sub>reg</sub> differentiation. The Hogquist group showed that T<sub>reg</sub> receive strong TCR signals in the thymus and the periphery when analysed using a Nur77(Nr4a1)-GFP transgenic reporter [44]. Using Nr4a3–Tocky, we have shown that Foxp3 expression in the thymus occurs in T cells that have received temporally persistent TCR signals [27]. Furthermore, using Foxp3–Tocky we showed that Foxp3 transcription is initiated in non-T<sub>reg</sub> cells during inflammation in the periphery [26]. In humans, activation-induced Foxp3 in conventional T cells suppresses their proliferation and cytokine production in a cell-intrinsic manner [45]. In addition, activated conventional T cells can express both Foxp3 and cytotoxic T lymphocyte antigen-4 (CTLA-4), and thereby acquire the suppressive function that is dependent upon CTLA-4 [46]. These suggest that Foxp3 has a role in negative feedback regulation of T cell activation in co-operation with other immunoregulatory molecules, including CTLA-4. Foxp3 transcription, therefore, is thus under the control of TCR signals in both the thymus and the periphery. In addition, in normal homeostasis, T<sub>reg</sub> naturally arising memory-phenotype T cells are self-reactive and receive ‘tonic’ TCR signals in the periphery [27,44]. Considering this evidence, the biological meaning of TCR signal-induced Foxp3 expression includes two situations: (i) antigen recognition-induced Foxp3 transcription in Foxp3<sup>+</sup> cells (conventional T cells; non-T<sub>reg</sub>) in the thymus and the periphery; and (ii) the effects of tonic TCR signals in Foxp3<sup>+</sup> T<sub>reg</sub>.

In line with the evidence of Foxp3 expression upon TCR stimulation, the gene regulatory regions of the Foxp3 gene are bound by transcription factors downstream of major branches of the TCR signalling pathway, including nuclear factor of activated T cells (NFAT) and activator protein 1 (API) [47], the nuclear factor kappa B (NF-B) components c-Rel and p65 [32,48-50], cyclic AMP response element-binding protein (CREB) [51] and Nr4a proteins [52] (Fig. 2).

Nr4a proteins (Nr4a1, Nr4a2 and Nr4a3) bind to their target sequences as homodimers or heterodimers and regulate transcription [53,54]. Foxp3<sup>+</sup> T<sub>reg</sub> differentiation is abolished in Nr4a1/2/3 triple knock-out (KO) mice and Nr4a1/3 double KO, and these mice develop fatal autoinflammatory disease [52]. Nr4a proteins bind to the Foxp3 promoter upon anti-CD3 stimulation [52] and retroviral gene transduction of Nr4a2 or Nr4a3 induces Foxp3 transcription [55]. Importantly, however, Nr4a triple KO lack...
not only Foxp3+ Tregs but also most of the double-positive (DP) cell population [52], which suggests that the Treg reduction in these KO mice is a consequence of defective regulation of positive and negative selection. Meanwhile, we have identified Nr4a3 as the gene that is the most correlated with the effects of TCR signals in the thymus and the periphery, followed by Nr4a1 [27]. Specifically, using canonical correspondence analysis (CCA) [56], we analysed the transcriptome data set of thymic T cell populations and that of resting and anti-CD3 stimulated peripheral T cells, and thereby identified the genes that were correlated with both thymic T cells under selection (in-vivo TCR signals) and peripheral T cell activation [27]. By developing Nr4a3–Tocky, we have shown that temporally persistent TCR signals sustain Nr4a3 transcription and initiate Foxp3 transcription [27]. This leads to the new model for Nr4a, that the recognition of cognate antigen conveys persistent TCR signals, which induce and accumulate Nr4a proteins and thereby control thymic selection and differentiation processes including Treg differentiation.

**Foxp3 transcription-enhancing cytokine signals.** Foxp3 transcription is activated by IL-2 signalling in the presence of TCR stimulation and TGF-β signalling [18]. However, it is unknown whether these cytokine signals can regulate Foxp3 transcription independently from TCR signalling.

IL-2 signalling is a central cytokine for T cell activation, proliferation and differentiation [21]. The expression of CD25 (IL-2R α-chain) is induced by TCR and CD28 signals and forms the high-affinity IL-2R, together with IL-2R β-chain (CD122) and the common γ-chain (CD132) [57,58]. IL-2 binding to IL-2R triggers phosphorylation of signal transducer and activator of transcription (STAT)-4 and STAT-5 by the associated kinases Janus kinase (Jak)1 and Jak3, which promote cell cycle entry and proliferation of TCR-stimulated T cells [59]. In addition to the role in T cell activation, CD25 is also a surface marker for Treg in mice [60] and humans [61]. In fact, IL-2 signalling is functional in Treg. Phosphorylated STAT-5 binds to the promoter and CNS2 and activates Foxp3 transcription [62,63]. KO mice for the genes that are involved in IL-2 signalling (Il2 [64], Il2ra [64], Il2rb [65], Jak3 [66] and Stats1/Stats5b [67]) have reduced Foxp3+ T cells in the thymus and periphery. Thus, IL-2 signalling is required for the activation of Foxp3 transcription, most probably during both the early phase of Treg differentiation as well as the maintenance of both Foxp3 transcription and the Treg population. Considering the primary role of IL-2 for the activation and proliferation of T cells [21], this suggests a role of Foxp3 as a sensor for the IL-2 abundance in the environment surrounding individual T cells. In other words, when T cells are activated IL-2 becomes abundant, which enhances Foxp3 expression in nearby T cells. Given that IL-2R expression in Treg absorbs IL-2 and suppresses IL-2-mediated T cell proliferation [68], the size of the T cell population may be self-regulated through the feedback mechanism involving IL-2, CD25 and Foxp3 [38].

TGF-β signalling has multi-faceted effects on tissue development and regeneration, inflammation and cancer in a context-dependent manner [69]. The importance of TGF-β signalling in T cells is recognized particularly in mucosal and tumour immunity [70]. The transcriptional response of T cells to TGF-β signalling is also context-dependent, and is illustrated by the reciprocal differentiation of T helper type 17 (Th17) and Treg by IL-6 and IL-2, respectively, in the presence of TGF-β [71,72]. TGF-β signal-activated Mothers Against DPP Homologue 3 (SMAD3) binds to the CNS1 of the Foxp3 gene [32,73]. However, the genetic deletion of the SMAD-binding site does not change the frequencies of Treg-binding site in the thymus.
Importantly, the expression of Foxp3 in Tregs is reduced protein [32] and STAT-5 [63], which makes an active complex with Runx1 [83], Foxp3 including the Runx/Cbf-β complex [78‒81], Ets-1 [82], CNS2 is bound by several key transcription factors, while inhibiting the differentiation of Tregs in the CD45RB(high) T cell-mediated colitis model [75].

Veldhoen and Stockinger have proposed the model that TGF-β skews CD4+ T cell differentiation from Th1 to Th17 [76], and as such, TGF-β may shift T cells from the Th1–Th2 axis to the Th17–Treg axis. In the TGF-β-rich microenvironment, such as in the intestines, tumour or damaged tissues undergoing regeneration and remodelling, the persistence of pathogen or autoantigen may activate monocytes and dendritic cells, and thereby repress Foxp3 transcription and promote Th17 differentiation, as observed in rheumatoid arthritis patients [77]. In contrast, once the activation of innate immune cells is terminated, Foxp3 transcription may be initiated in antigen-reactive T cells, as observed by Foxp3–Tocky [26], especially when adjacent T cells are proliferating and producing IL-2, inducing the resolution of inflammation.

**Mechanisms for the consolidation and tuning of Foxp3 transcription – the role of autoregulatory transcriptional circuit for the Foxp3 gene**

The maintenance of Foxp3 transcription in Treg requires conserved non-coding sequences 2 (CNS2), which includes the widely studied Treg-specific demethylated region, TSDR [33]. The cytosine–phosphate–guanine (CpG) motifs in the TSDR are methylated in non-Treg cells and fully demethylated in thymic Treg [22,33]. The genetic deletion of CNS2 results in the reduction of Foxp3 expression in thymic Treg but does not affect Foxp3 induction in vitro [32]. CNS2 is bound by several key transcription factors, including the Runx/Cbf-β complex [78–81], Ets-1 [82], which makes an active complex with Runx1 [83], Foxp3 protein [32] and STAT-5 [63].

Foxp3 binding to CNS2 is dependent upon Runx1/Cbf-β [32]. Importantly, the expression of Foxp3 in Treg is reduced in both Cbf-β-deficient Treg [78] and CNS2-deleted Treg [34]. CNS2 is required for maintaining the number of Treg in the periphery during homeostasis and is also important for sustaining Foxp3 expression during inflammation [7,34]. CNS2-deleted Treg lose Foxp3 expression in the presence of proinflammatory cytokines, including IL-4 and IL-6, and become effector T cells to enhance autoimmune inflammation in mice [7]. Furthermore, analysis of TCR repertoires in human Treg also suggests the dynamic regulation of both CD25 and Foxp3 on T cells in rheumatoid arthritis [84]. These data together suggest that, although Foxp3 expression is commonly recognized to be stable, it is in fact dynamically regulated in Foxp3+ Treg during homeostasis and during immune responses.

Our recent investigations using Foxp3–Tocky have shown that, intriguingly, resting Treg have intermittent Foxp3 transcription, while activated effector Treg with high expression of immunoregulatory molecules (including CTLA-4 and IL-10) have more sustained Foxp3 transcription throughout time [26]. The phenotype of these effector Treg, with temporally persistent Foxp3 transcription is in fact very similar to those of the effector Treg that are dependent upon Myb [85] and the CD45RB(high) CD62L low activated Treg that are dependent upon TCR signals [35], which supports the model that TCR signals induce temporally persistent Foxp3 transcription and thereby enhance the suppressive phenotype of Treg. Furthermore, by analysing female mice with heterozygosity for a hypomorphic Foxp3 mutant (namely, Scuffy mutation), Foxp3 protein sustains the temporally persistent Foxp3 transcriptional dynamics that promote effector Treg functions [26]. In the thymus, the active demethylation of the TSDR occurs only after the initiation of Foxp3 transcription and when Foxp3 transcription is highly sustained over time [27]. These indicate that Foxp3 protein and the Foxp3 gene form an autoregulatory loop that consolidates the Treg-type TSDR demethylation during thymic differentiation [27], and tunes Foxp3 transcriptional activities and thereby activates their suppressive activity during inflammation [26]. Given the critical roles of the Runx1/Cbf-β complex in the maintenance of Foxp3 expression and the Foxp3–Runx1 interaction in Treg differentiation and function, it is plausible that this autoregulatory transcriptional circuit is formed via the binding of Foxp3–Runx1/Cbf-β complex [32] to CNS2 of the Foxp3 gene (Fig. 2).

**Dynamic regulation of epigenetic modifications and chromatin architecture of the Foxp3 gene**

TCR-induced Foxp3 transcriptional activities can be opposed by epigenetic mechanisms for silencing Foxp3 transcription. The SUMO E3 ligase Pias3 binds to the Foxp3 promoter, and Pias1 KO mice have increased frequencies of Foxp3+ cells in CD4+ T cells and reduced methylation of histone H3 at Lys9 (H3K9), which is a hallmark of repressed genes [86]. The DNA methyltransferase DNA (cytosine-5)-methyltransferases (Dnmt1) and the high mobility group transcription factors Tcf1 and Lef1 constitutively repress Foxp3 transcription in CD8+
T cells, as Dnmt1<sup>−/−</sup> or Tcf1<sup>−/−</sup>-Lef1<sup>−/−</sup> double KO permits the differentiation of Foxp3<sup>+</sup>CD8<sup>+</sup> T cells, which are rarely found in normal mice [87,88]. In addition, the induction of Foxp3 expression in Dnmt1<sup>−/−</sup>-T does not require TGF-β [87], suggesting that TGF-β probably modulates epigenetic mechanisms in normal mice. Strong TCR signalling <i>in vitro</i> causes the accumulation of Dnmt1 at the Foxp3 promoter, which can lead to increased CpG methylation and inhibition of Foxp3 transcription [89]. Thus, TGF-β may be important for tuning Dnmt1 expression during T cell activation.

Foxp3−Tocky has shed light on the dynamics of Foxp3 epigenetic regulation following the initiation of Foxp3 transcription. Importantly, Foxp3 transcription precedes the demethylation of TSDR in the thymus. Both thymic new Foxp3 expressors, which are identified by Tocky [27], and immature CD24<sup>hi</sup>Foxp3<sup>+</sup>CD4SP by Foxp3-EGFP mice [90] have fully methylated TSDR. The active process for TSDR demethylation occurs only after Foxp3 transcription is sustained over time and the Foxp3 autoregulatory loop is formed [26]. Collectively, the interactions between Foxp3-inducing and inhibiting factors occur during the early phase of T<sub>reg</sub> differentiation when the Foxp3 gene is still ‘silenced’, and we would therefore hypothesize that Foxp3 protein may also have roles in dynamically regulating the epigenetic modifications of the Foxp3 gene. Future studies could therefore address the role of Foxp3 in the dynamic regulation of chromatin architecture, which can be investigated by chromatin conformation capture (3C) and derivative methods (e.g. Hi-C). For example, the Zheng group showed that, using 3C, NFAT activation induces the interaction of the TSDR-containing CNS2 with the Foxp3 promoter, which facilitates enhanced Foxp3 transcription [34]. Using Hi-C and clustered regularly interspaced short palindromic repeats (CRISPR)-mediated mutation, the Zhao group showed that the mixed lineage leukaemia (MLL) family methyltransferase MLL4 binds to ~8.5k upstream enhancer of the Foxp3 gene, and makes a chromatin loop to promote the monomethylation of histone H3 at Lys4 (H3K4me1) in the promoter and CNS3, which activates Foxp3 transcription [91]. The chromatin organizing factor special AT-rich sequence binding protein 1 (SATB1) is also involved in activating Foxp3 transcription in the thymus, as the genetic deletion of SATB1 results in the marked reduction of Foxp3<sup>+</sup> T<sub>reg</sub> and the accumulation of thymic CD25<sup>+</sup>Foxp3<sup>+</sup> T<sub>reg</sub> precursors with reduced enhancer activity [which are identified by acetylation of histone H3 at Lys27 (H3K27ac)] [92]. Thus, it is likely that chromatin remodelling of the Foxp3 gene underlies the temporally dynamic Foxp3 autoregulatory loop, suggesting that the former is also induced dynamically through the interactions between Foxp3 protein and key chromatin organizers and epigenetic regulators. In addition, as those chromatin organizers and epigenetic regulators control not only the Foxp3 gene but also other genes, the chromatin remodelling of Foxp3-target genes may be also induced dynamically in activated T<sub>reg</sub> and differentiating T<sub>reg</sub>. Future studies, therefore, should investigate the role of Foxp3 protein and its co-factors in the temporally dynamic regulation of chromatin structure within and outside the Foxp3 gene region.

**Dynamic Foxp3 expression <i>in vivo</i>: perspectives for basic immunology and clinical relevance**

After the emergence of single-cell technologies and the Tocky tool, studies on T cell regulation are shifting from the stability and plasticity of T<sub>reg</sub> to the investigation of temporal changes in Foxp3-mediated mechanisms <i>in vivo</i>. Our analysis of T<sub>reg</sub> in peripheral immune compartments show that, in non-inflammatory conditions, Foxp3 transcription is most probably modelled by intermittent gene activity [26]. This intermittent transcription may offer an explanation for the low frequency of T<sub>reg</sub> cells with detectable Foxp3 transcripts in T<sub>reg</sub> cells analysed by single-cell RNA-seq [93,94], although these data sets have limitations due to shallow sequencing depths. Given that the temporal changes in Foxp3 transcription control T<sub>reg</sub> function and effector T<sub>reg</sub> differentiation, future work will investigate the molecular mechanisms that control the real-time transcribing of the Foxp3 gene, which can be analysed by the Tocky system. In addition, in line with the temporally dynamic regulation of Foxp3 transcription <i>in vivo</i>, the significance of thymic and peripheral T<sub>reg</sub> markers needs to be readdressed. Our investigation using Foxp3−Tocky has confirmed that the expression of Neuropilin 1 [95] and Helios [96] are dynamically regulated in Tregs according to Foxp3 transcription dynamics [26], and therefore are not faithful markers of thymic T<sub>reg</sub> as has been noted previously in the literature [97].

Importantly, clinical studies and immunotherapy development may be benefited by the endorsement of the dynamic perspective. Whether targeting T<sub>reg</sub> or not, immunotherapy may dynamically change Foxp3 transcription. If these dynamic responses are clarified, immunotherapy targeting T cells may be better designed with a more tailored strategy, as we recently showed by manipulating Foxp3 transcriptional dynamics through targeting inflammation-reactive effector T<sub>reg</sub> by OX40 (CD134) and tumour necrosis factor receptor II (Tnfrsf1b which are expressed specifically in T<sub>reg</sub> with temporally persistent Foxp3 transcription [26]. We therefore envisage that the investigation of dynamic changes in molecular mechanisms during T cell responses <i>in vivo</i> will improve the predictability of
preclinical studies and thereby contribute to the development of new immunotherapies for autoimmune and cancer patients.

**Acknowledgements**

D. B. is funded by a University of Birmingham Fellowship. M. O. is a David Phillips Fellow (BB/J013951/2) from the Biotechnology and Biological Sciences Research Council (BBSRC).

**Disclosures**

The authors declare that no conflicts of interest exist in relation to this paper.

**References**

1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; **133**:775–87.
2. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; **30**:531–64.
3. Hsieh CS, Lee HM, Lio CW. Selection of regulatory T cells in the thymus. Nat Rev Immunol 2012; **12**:157–67.
4. Dujardin HC, Burlen-Defranoux O, Bouconet L, Vieira P, Cumano A, Bandeira A. Regulatory potential and control of Foxp3 expression in newborn CD4+ T cells. Proc Natl Acad Sci USA 2004; **101**:14473–8.
5. Samy ET, Wheeler KM, Roper RJ, Teuscher C, Tung KS. Cutting edge: autoimmune disease in 3 thymectomized mice is actively controlled by endogenous disease-specific regulatory T cells. J Immunol 2008; **180**:4366–70.
6. Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X et al. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 2013; **39**:49–62.
7. Feng Y, Arvey A, Chinen T, van der Veeken J, Gasteiger G, Rudensky AY. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. Cell 2014; **158**:749–63.
8. Beyersdorf N, Gaupp S, Balbach K et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 2005; **202**:445–55.
9. Hüsing T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol 2012; **12**:317.
10. Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; **355**:1018–28.
11. Eastwood D, Findlay L, Poole S et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 2010; **161**:512–26.

© 2018 The Authors. *Clinical & Experimental Immunology* published by John Wiley & Sons Ltd on behalf of British Society for Immunology, *Clinical and Experimental Immunology*, **00**:00–00
27. Bending D, Martin PP, Padurarau A et al. A timer for analyzing temporally dynamic changes in transcription during differentiation in vivo. J Cell Biol 2018; 217:2931–50.
28. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22:329–41.
29. Haribhai D, Lin W, Relland LM, Truong N, Williams CB, Chatila TA. Regulatory T cells dynamically control the primary immune response to foreign antigen. J Immunol 2007; 178:2961–72.
30. Rubtsov YP, Niec RE, Josefowicz S et al. Stability of the regulatory T cell lineage in vivo. Science 2010; 329:1667–71.
31. Subach FV, Subach OM, Gundorov IS et al. Monomeric fluorescent timers that change color from blue to red report on cellular trafficking. Nat Chem Biol 2009; 5:118–26.
32. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010; 463:808–12.
33. Floess S, Freyer J, Siewert C et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLOS Biol 2007; 5:e38.
34. Li X, Liang Y, LeBlanc M, Benner C, Zheng Y. Function of a Foxp3 cis-element in protecting regulatory T cell identity. Cell 2014; 158:734–48.
35. Levine AG, Arvey A, Jin W, Rudensky AY. Continuous requirement for the TCR in regulatory T cell function. J Immunol 2014; 193:1070–8.
36. Vahl JC, Drees C, Heger K et al. Continuous T cell receptor signals maintain a functional regulatory T cell pool. Immunity 2014; 41:722–36.
37. Li MO, Rudensky AY. T cell receptor signalling in the control of regulatory T cell differentiation and function. Nat Rev Immunol 2016; 16:220–30.
38. Ono M, Tanaka RJ. Controversies concerning thymus-derived regulatory T cells: fundamental issues and a new perspective. Immunol Cell Biol 2016; 94:3–10.
39. Jordan MS, Boesteau A, Reed AJ et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat. Immunol 2001; 2:301–6.
40. Bautista JL, Lio CW, Lathrop SK et al. Intraclonal competition limits the fate determination of regulatory T cells in the thymus. Nat Immunol 2009; 10:610–9.
41. Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T cell repertoire: what thymocytes see (and don’t see). Nat Rev Immunol 2014; 14:377.
42. Itoh M, Takahashi T, Sakaguchi N et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999; 162:5317–26.
43. Curotto de Lafaille MA, Lino AC, Kutchukhidze N, Lafaille JJ. CD25– T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J Immunol 2004; 173:7259–68.
44. Moran AE, Holzapfel KL, Xing Y et al. T cell receptor signal strength in Treg and INKT cell development demonstrated by a novel fluorescent reporter mouse. J Exp Med 2011; 208:1279–89.
45. McMurchy AN, Gillies J, Gazi MC et al. A novel function for FOXP3 in humans: intrinsic regulation of conventional T cells. Blood 2013; 121:1265–75.
46. Zheng Y, Manzotti CN, Burke F et al. Acquisition of suppressive function by activated human CD4+ CD25– T cells is associated with the expression of CTLA-4 not Foxp3. J Immunol 2008; 181:1683–91.
47. Mantel PY, Ouaked N, Ruckert B et al. Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol 2006; 176:3593–602.
48. Isomura I, Palmer S, Grumont RJ et al. c-Rel is required for the development of thymic Foxp3+ CD4 regulatory T cells. J Exp Med 2009; 206:3001–14.
49. Long M, Park SG, Strickland I, Hayden MS, Ghosh S. Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity 2009; 31:921–31.
50. Ruan Q, Kameswaran V, Tone Y et al. Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhancerosome. Immunity 2009; 31:932–40.
51. Kim HP, Leonard WJ. CREB/ATF-dependent T cell receptor-induced Foxp3 gene expression: a role for DNA methylation. J Exp Med 2007; 204:1543–51.
52. Sekiya T, Kashiwagi I, Yoshida R et al. Nr4a receptors are essential for thymic regulatory T cell development and immune homeostasis. Nat Immunol 2013; 14:230–7.
53. Maira M, Martens C, Philips A, Drouin J. Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Mol Cell Biol 1999; 19:7549–57.
54. Duren RP, Boudreaux SP, Connelly OM. Genome wide mapping of NR4A binding reveals cooperativity with ETS factors to promote epigenetic activation of distal enhancers in acute myeloid leukemia cells. PLOS ONE 2016; 11:e0150450.
55. Sekiya T, Kashiwagi I, Inoue N et al. The nuclear orphan receptor Nr4a2 induces Foxp3 and regulates differentiation of CD4+ T cells. Nat Commun 2011; 2:269.
56. Ono M, Tanaka RJ, Kano M. Visualisation of the T cell receptor signal by peripheral expansion. J Immunol 2004; 173:7259–68.
57. Shimizu A, Kondo S, Sabe H, Ishida N, Honjo T. Structure and function of the interleukin 2 receptor. J Exp Med 2011; 208:1279–89.
58. Gaffen SL. Signaling domains of the interleukin 2 receptor. J Exp Med 2011; 208:1279–89.
Foxp3 transcriptional dynamics in regulatory T cells

59. Smith GA, Uchida K, Weiss A, Taunton J. Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling. Nat Chem Biol 2016; 12:373.

60. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151–64.

61. Baecher-Allan C, Brown JA, Freeman GI, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167:1245–53.

62. Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA. IL-2 receptor beta-dependent STAT3 activation is required for the development of Foxp3+ regulatory T cells. J Immunol 2007; 178:280–90.

63. Yao Z, Kanno Y, Kerenyi M et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 2007; 109:4368–75.

64. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6:1142–51.

65. Chinen T, Kannan AK, Levine AG et al. An essential role for the IL-2 receptor in Treg cell function. Nat Immunol 2016; 17:1322–33.

66. Antov A, Yang L, Vig M, Baltimore D, Van Parijs L. Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol 2003; 171:3435–41.

67. Snow JW, Abraham N, Ma MC, Herndier BG, Pastuszak AW, Goldsmith MA. Loss of tolerance and autoimmunity affecting multiple organs in STAT5A/5B-deficient mice. J Immunol 2003; 171:5042–50.

68. Feinerman O, Jentsch G, Tkach KE et al. Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response. Mol Syst Biol 2010; 6:437.

69. Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol 2012; 13:616.

70. Oh SA, Li MO. TGF-β; guardian of T cell function. J Immunol 2013; 191:3973–9.

71. Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235–8.

72. Laurence A, Tato CM, Davidson TS et al. Interleukin-2 signaling via STAT5 constrains T helper 1 cell generation. Immunity 2007; 26:371–81.

73. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2007; 9:194.

74. Schlenner SM, Weigmann B, Ruan Q, Chen Y, von Boehmer H. Smad3 binding to the foxp3 enhancer is dispensable for the development of regulatory T cells with the exception of the gut. J Exp Med 2012; 209:1529–35.

75. Durant L, Watford WT, Ramos HL et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 2010; 32: 605–15.

76. Veldhoen M, Stockinger B. TGFβ1, a Jack of all trades: the link with pro-inflammatory IL-17-producing T cells. Trends Immunol 2006; 27:358–61.

77. Evans HG, Gullick NJ, Kelly S et al. In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses. Proc Natl Acad Sci USA 2009; 106:6232–7.

78. Kitoh A, Ono M, Naoe Y et al. Indispensable role of the Runx1-Cbfβ transcription complex for in vivo-suppressive function of Foxp3+ regulatory T cells. Immunity 2009; 31:609–20.

79. Ono M, Naguchi H, Ohkura N et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007; 446:685–9.

80. Rudra D, Egawa T, Chong MM, Treuting P, Littman DR, Rudensky AY. Runx-Cbfβ complexes control expression of the transcription factor Foxp3 in regulatory T cells. Nat Immunol 2009; 10:1170–7.

81. Bruno L, Mazzarella L, Hoogenkamp M et al. Runx proteins regulate Foxp3 expression. J Exp Med 2009; 206:2329–37.

82. Polansky JK, Schreiber L, Thelemann C et al. Methylation matters: binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells. J Mol Med (Berl) 2010; 88:1029–40.

83. Shrivastava T, Mino K, Babayeva ND, Baranovskaya OI, Rizzino A, Tahirov TH. Structural basis of Ets1 activation by Runx1. Leukemia 2014; 28:2040–8.

84. Bending D, Giannakopoulou E, Lom H, Wedderburn LR. Synovial regulatory T cells occupy a discrete TCR niche in human arthritis and require local signals to stabilize FOXP3 protein expression. J Immunol 2015; 195:5616–24.

85. Dias S, D’Amico A, Cretney E et al. Effector regulatory T cell differentiation and immune homeostasis depend on the transcription factor myb. Immunity 2017; 46:78–91.

86. Liu B, Tahk S, Yee KM, Fan G, Shuai K. The ligase PIAS1 for the IL-2 receptor in Treg cell function. J Immunol 2003; 169:1151–64.
90. Toker A, Engelbert D, Garg G et al. Active demethylation of the Foxp3 locus leads to the generation of stable regulatory T cells within the thymus. J Immunol 2013; 190:3180–8.

91. Placek K, Hu G, Cui K et al. MLL4 prepares the enhancer landscape for Foxp3 induction via chromatin looping. Nat Immunol 2017; 18:1035–45.

92. Kitagawa Y, Ohkura N, Kidani Y et al. Guidance of regulatory T cell development by Satb1-dependent super-enhancer establishment. Nat Immunol 2016; 18:173.

93. Delacher M, Imbusch CD, Weichenhan D et al. Genome-wide DNA-methylation landscape defines specialization of regulatory T cells in tissues. Nat. Immunol 2017; 18:1160–72.

94. Zemmour D, Zilionis R, Kiner E, Klein AM, Mathis D, Benoist C. Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR. Nat Immunol 2018; 19:291–301.

95. Weiss JM, Bilate AM, Gobert M et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med 2012; 209:1723–42, S1.

96. Thornton AM, Korty PE, Tran DQ et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010; 184:3433–41.

97. Szurek E, Cebula A, Wojciech L et al. Differences in expression level of helios and neuropilin-1 do not distinguish thymus-derived from extrathymically-induced CD4+Foxp3+ regulatory T cells. PLOS ONE 2015; 10:e0141161.